NEUP•benzinga•
Neuphoria Releases Review Of 2024 And Highlights 2025 Plans Including $15M Payment From Merck Extending Company's Cash Runway To Q3 2026 And Phase 3 Affirm-1 Trial of BNC210 In Social Anxiety Disorder Progressing As Planned With Topline Readout Anticipate
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 15, 2025 by benzinga